at Nasdaq.com (Tue, 2:51PM)
Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical studies of Merck's MK-8931 drug for treating Alzheimer's disease. Flutemetamol, which performed well in its own Phase III trials, helps detect beta amyloid deposits in the brain. The build-up of beta amyloid has been associated with Alzheimer's. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Mon, 12:38PM)
at Zacks.com (Jan 16, 2015)
at Zacks.com (Jan 15, 2015)
at Nasdaq.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs